Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...

Exicure was an expiring company with no money or active pipeline. | A couple of months ago, Exicure was an expiring company ...

Robert F. Kennedy Jr. will be pulling his investments from two biotechs if he is confirmed to lead the U.S. Department of ...

Beta Bionics has set the terms for its plan to go public, with a goal of raising at least $114 million to support its ...

As multisite clinical research corporations (MCRCs) proliferate to meet the increased demand for larger clinical trials that ...

Biogen has been in the news recently after longtime partner Sage Therapeutics filed a lawsuit against the company after ...

Novo Nordisk is opening a new front in its fight against sickle cell disease, inking a deal with IMMvention Therapeutix to co ...

For the full calendar of 2024, Abbott recorded sales of $41.95 billion, following the launches last year of a new heart valve ...

Following last year’s launches of several all-in-one CRO offerings, Lindus Health is starting 2025 strong by closing a $55 ...

A year after going public, ArriVent BioPharma is continuing to bolster its antibody-drug conjugate pipeline via licensing ...

Tris Pharma has pointed to a phase 3 win for its pain relief drug as demonstrating the candidate’s potential to help resolve the opioid crisis. | Tris Pharma has pointed to a phase 3 win for its pain ...

Among his first actions as president, Donald Trump has rescinded an executive order signed during the Biden administration ...